Journal of Neuroimmunology
Volume 220, Issue 1 , Pages 69-78, 30 March 2010

Reduction of cell proliferation and potentiation of Fas-induced apoptosis by the selective kappa-opioid receptor agonist U50 488 in the multiple myeloma LP-1 cells

  • Céline Kerros

      Affiliations

    • C.K. is a recipient of the Ministère de l'enseignement supérieur et de la recherche.
    • ,
  • Isabelle Brood
    • ,
  • Brigitte Sola
    • ,
  • Philippe Jauzac

      Affiliations

    • In memory of Philippe Jauzac.
    • ,
  • Stéphane Allouche

      Affiliations

    • Corresponding Author InformationCorresponding author. Laboratoire de Biochimie, Centre Hospitalier et Universitaire, Avenue côte de nacre, 14033 Caen cedex, France. Tel.: +33 231065419; fax: +33 231064985.

Université de Caen, Laboratoire de biologie moléculaire et cellulaire de la signalisation, UPRES-EA 3919, IFR 146 ICORE, avenue côte de Nacre, 14032 Caen, France

Received 17 November 2009; received in revised form 12 January 2010; accepted 19 January 2010. published online 18 February 2010.

Abstract 

As opioid receptors modulate proliferation and apoptosis of immune cells, we hypothesized that they could reduce malignant haematopoietic cells. After screening, we selected the human multiple myeloma LP-1 cells which express mu- (MOP-) and kappa-opioid receptors (KOP-R). U50 488 produces a modest but significant decrease in viability associated with an arrest in the G0/G1 phase, but not antagonized by NorBNI and not associated with modulation of p21Cip1, p27Kip1 or p53 expression. In contrast, no effect was observed with dynorphin, U69 593 and morphine.

In conclusion, the anti-proliferative effects of U50 488 are not mediated by KOP-R in the LP-1 cells.

Keywords: Opioid receptor, Multiple myeloma, Apoptosis, Cell proliferation

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

PII: S0165-5728(10)00015-9

doi:10.1016/j.jneuroim.2010.01.010

Journal of Neuroimmunology
Volume 220, Issue 1 , Pages 69-78, 30 March 2010

Article Tools

* Image Usage & Resolution